Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Department of Pediatrics, Chengdu Shangjin Nanfu Hospital, Chengdu, China.
Mol Genet Genomic Med. 2022 Jul;10(7):e1962. doi: 10.1002/mgg3.1962. Epub 2022 May 19.
PRKAG2 cardiac syndrome is a rare autosomal dominant genetic disorder caused by a PRKAG2 gene variant. There are several major adverse cardiac presentations, including hypertrophic cardiomyopathy (HCM) and life-threatening arrhythmia. Two cases with pathogenic variants in the PRKAG2 gene are reported here who presents different cardiac phenotypes.
Exome sequencing and variant analysis of PRKAG2 were performed to obtain genetic data, and clinical characteristics were determined.
The first proband was a 9-month-old female infant (Case 1), and was identified with severe DCM and resistant heart failure. The second proband was a 10-year-old female infant (Case 2), and presented with HCM and ventricular preexcitation. Exome sequencing identified a de novo c.425C > T (p.T142I) heterozygous variant in the PRKAG2 gene for Case 1, and a c.869A > T (p.K290I) for Case 2. The mutated sites in the protein were labeled and identified as p.K290 in the CBS domain and p.T142 in the non-CBS domain. Differences in the molecular functions of CBS and non-CBS domains have not been resolved, and variants might lead to the different cardiomyopathy phenotypes. Single-cell RNA analysis demonstrated similar expression levels of PRKAG2 in cardiomyocytes and conductive tissues. These results suggest that the arrhythmia induced by the PRKAG2 variant was the primary change, and not secondary to cardiomyopathy.
In summary, this is the first case report to describe a DCM phenotype with early onset in patients possessing a PRKAG2 c.425C > T (p.T142I) pathogenic variant. Our results aid in understanding the molecular function of non-CBS variants in terms of the disordered sequence of transcripts. Moreover, we used scRNA-seq to show that electrically conductive cells express a higher level of PRKAG2 than do cardiomyocytes. Therefore, variants in PRKAG2 are expected to also alter the biological function of the conduction system.
PRKAG2 心脏综合征是一种由 PRKAG2 基因突变引起的罕见常染色体显性遗传性疾病。主要有几种严重的心脏表现,包括肥厚型心肌病(HCM)和危及生命的心律失常。本文报告了两例 PRKAG2 基因致病性变异患者,他们表现出不同的心脏表型。
对 PRKAG2 进行外显子组测序和变异分析,获取遗传数据,并确定临床特征。
第一个先证者是一名 9 月龄女性婴儿(病例 1),被诊断为严重的 DCM 和难治性心力衰竭。第二个先证者是一名 10 岁女性婴儿(病例 2),表现为 HCM 和心室预激。外显子组测序在 PRKAG2 基因中发现了一例新生杂合 c.425C>T(p.T142I)变异,另一个为 c.869A>T(p.K290I)。该蛋白的突变部位被标记并鉴定为 CBS 结构域中的 p.K290 和非 CBS 结构域中的 p.T142。尚未解决 CBS 和非 CBS 结构域的分子功能差异,变异可能导致不同的心肌病表型。单细胞 RNA 分析表明,心肌细胞和传导组织中 PRKAG2 的表达水平相似。这些结果表明,PRKAG2 变异引起的心律失常是主要变化,而不是继发于心肌病。
总之,这是首例描述携带 PRKAG2 c.425C>T(p.T142I)致病性变异的患者出现早发性 DCM 表型的病例报告。我们的结果有助于了解非 CBS 变异在转录物序列紊乱方面的分子功能。此外,我们使用 scRNA-seq 显示电传导细胞比心肌细胞表达更高水平的 PRKAG2。因此,PRKAG2 的变异预计也会改变传导系统的生物学功能。